Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 29, 2026

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells
10:37

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells

Published on: March 14, 2021

Cardiac organoids bridge translational gaps in 3R-compliant safety testing.

Cyrielle Jajkiewicz1, Mohamed Chahine2

  • 1CERVO Brain Research Centre, Quebec City, Quebec, Canada.

Stem Cell Research
|June 27, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antisense-mediated gene therapy targeting DMPK restores cardiac ion channel function and electrical stability in myotonic dystrophy type 1.

Heart rhythm·2026
Same author

Generation of a lymphoblastoid-derived induced pluripotent stem cell line (CBRCULi021-A) from a healthy donor for disease modeling.

Stem cell research·2026
Same author

Revisiting viral reprogramming: Measles virus as a robust platform for high-quality iPSC generation.

Molecular therapy. Advances·2026
Same author

C-Terminus of Ca<sub>v</sub>1.3 L-Type Ca<sup>2+</sup> Channel Upregulates Its Own Gene Expression.

Cells·2026
Same author

Therapeutic Strategies Targeting the Molecular Pathogenesis of Myotonic Dystrophy Type 1: Current Status and Future Directions.

Molecular diagnosis & therapy·2026
Same author

COMPUTATIONAL ANALYSIS OF THE NOVEL LQT3 MUTATIONS G1481V AND Q1491H IN MYOCARDIAL AND PURKINJE CELLS.

Annual Modeling and Simulation Conference (ANNSIM). Annual Modeling and Simulation Conference (Online)·2026

Human cardiac organoids offer a promising solution to predict drug cardiotoxicity. These 3D models bridge the gap between cell cultures and animal studies, improving preclinical safety assessments.

Area of Science:

  • Cardiovascular Research
  • Drug Safety Evaluation
  • Regenerative Medicine

Background:

  • Cardiotoxicity is a major cause of drug failure in late-stage development.
  • Current preclinical models (animals, 2D cell cultures) have significant limitations in predicting human drug responses.
  • A translational gap exists between cellular assays and whole-organ physiology.

Purpose of the Study:

  • To review the potential of human cardiac organoids as a novel platform for cardiovascular safety assessment.
  • To evaluate their biological fidelity, functional capabilities, and disease modeling relevance.
  • To explore their integration into safety pharmacology frameworks for drug development.

Main Methods:

  • Critical evaluation of existing literature on human cardiac organoids.
Keywords:
3Rs (ReplacementCardiac organoidsCardiotoxicityDisease modelingEarly drug testingHuman induced pluripotent stem cells (hiPSC)ReductionRefinement)Safety pharmacology

More Related Videos

A Hypoxia-Reoxygenation Injury Model in Self-Assembling Human Cardioids
10:41

A Hypoxia-Reoxygenation Injury Model in Self-Assembling Human Cardioids

Published on: March 17, 2026

Related Experiment Videos

Last Updated: Jun 29, 2026

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells
10:37

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells

Published on: March 14, 2021

A Hypoxia-Reoxygenation Injury Model in Self-Assembling Human Cardioids
10:41

A Hypoxia-Reoxygenation Injury Model in Self-Assembling Human Cardioids

Published on: March 17, 2026

  • Assessment of their structural and functional maturity, including electromechanical coupling and multicellular interactions.
  • Analysis of their potential for modeling neurocardiac crosstalk and extracellular matrix remodeling.

    • Main Results:

    • Human cardiac organoids exhibit 3D architecture, coordinated conduction, and force generation, mimicking human heart physiology.
    • They offer a more physiologically relevant model compared to traditional methods, supporting complex cardiac functions.
    • Cardiac organoids show promise for implementing the 3Rs (Replacement, Reduction, Refinement) in drug development.

    Conclusions:

    • Human cardiac organoids represent a critical intermediate platform between cellular systems and whole-organ models for drug safety testing.
    • Further standardization and validation are needed to transition them into robust regulatory tools.
    • These organoids hold significant potential for predictive and ethically aligned cardiovascular safety assessments.